What happened: A new stroke thrombolytic — tenecteplase — marketed as TNKase — has received FDA approval, marking the first such advancement in nearly 30 years. Unlike alteplase (tPA), which ...

r-tPA (recombinant tissue-type plasminogen activator) and its variant, TNK (tenecteplase), are the currently approved thrombolytic drugs for the treatment of acute ischemic stroke, but they are ...

The transition from alteplase (TPA) to tenecteplase (TNK) in acute ischemic stroke (AIS) management is gaining traction due to TNK’s advantages in ease of administration and lower costs. Several ...

TNKase is a lab-made version of a natural protein called tPA, which helps break down blood clots. It sticks to fibrin, the protein that holds clots together, and triggers an enzyme to dissolve them.

Huo noted that there has never been a direct comparison between IA alteplase and IA TNK in the context of postthrombectomy treatment for stroke patients. The current phase III study, IA rhTNK-tPA ...

Background Tenecteplase (TNK) is a genetically modified variant of alteplase (TPA) and has been established as a non-inferior alternative to TPA in acute ischemic stroke (AIS). Whether TNK exerts ...

Introduction: Outcomes after thrombolysis with alteplase (tPA) versus tenecteplase (TNK) prior to endovascular thrombectomy (EVT) have not been directly compared in real-world data (RWD). We leveraged ...

Tenecteplase TNKase, a tissue plasminogen activator tPA, plays a vital role by rapidly dissolving blood clots that obstruct blood flow to the brain, thus restoring circulation and minimizing brain ...

The differential diagnosis of decompensation after receiving TNK or TPA includes anaphylaxis, intracranial bleeding, gastrointestinal (GI) bleeding, or progression of stroke. Because the patient ...

Data were included for 11 RCTs, with 3,788 patients treated with TNK and 3,757 patients treated with TPA. The researchers found that compared with TPA, TNK was associated with a higher likelihood ...